A judge has determined that Johnson & Johnson may not use a unit’s bankruptcy case to pressure tens of thousands of cancer victims to withdraw their lawsuits and accept an $8.9B settlement, Bloomberg’s Steven Church, Jonathan Randles, and Jef Feeley report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JNJ:
- Janssen submits supplemental application to FDA for Edurant
- Johnson & Johnson exec Fasolo sells 20,000 common shares
- Johnson & Johnson upgraded to Buy from Hold at Spin-Off Research
- Wall Street Goes the Irrational Route with Kenvue Stock (NYSE:KVUE)
- Johnson & Johnson price target raised to $175 from $171 at Barclays